Korean Drug Co. Ltd - Asset Resilience Ratio
Korean Drug Co. Ltd (014570) has an Asset Resilience Ratio of 25.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Korean Drug Co. Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Korean Drug Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 014570 asset base.
Liquid Assets Composition Over Time
This chart breaks down Korean Drug Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Korean Drug Co. Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩25.13 Billion | 25.41% |
| Total Liquid Assets | ₩25.13 Billion | 25.41% |
Asset Resilience Insights
- Very High Liquidity: Korean Drug Co. Ltd maintains exceptional liquid asset reserves at 25.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Korean Drug Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Korean Drug Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
F:ZEGA |
Drug Manufacturers - General | 0.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
Annual Asset Resilience Ratio for Korean Drug Co. Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Korean Drug Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.62% | ₩25.11 Billion ≈ $17.02 Million |
₩94.32 Billion ≈ $63.92 Million |
+5.29pp |
| 2024-12-31 | 21.33% | ₩18.96 Billion ≈ $12.85 Million |
₩88.89 Billion ≈ $60.24 Million |
+2.78pp |
| 2023-12-31 | 18.55% | ₩16.64 Billion ≈ $11.28 Million |
₩89.71 Billion ≈ $60.79 Million |
-9.21pp |
| 2022-12-31 | 27.76% | ₩26.23 Billion ≈ $17.78 Million |
₩94.52 Billion ≈ $64.05 Million |
-3.52pp |
| 2021-12-31 | 31.28% | ₩27.72 Billion ≈ $18.78 Million |
₩88.61 Billion ≈ $60.05 Million |
+4.80pp |
| 2020-12-31 | 26.48% | ₩22.07 Billion ≈ $14.95 Million |
₩83.34 Billion ≈ $56.48 Million |
+11.50pp |
| 2019-12-31 | 14.98% | ₩11.36 Billion ≈ $7.70 Million |
₩75.85 Billion ≈ $51.40 Million |
+3.16pp |
| 2018-12-31 | 11.82% | ₩8.62 Billion ≈ $5.84 Million |
₩72.96 Billion ≈ $49.45 Million |
+7.10pp |
| 2017-12-31 | 4.71% | ₩3.15 Billion ≈ $2.13 Million |
₩66.79 Billion ≈ $45.27 Million |
-1.58pp |
| 2016-12-31 | 6.30% | ₩3.99 Billion ≈ $2.71 Million |
₩63.41 Billion ≈ $42.97 Million |
+5.71pp |
| 2015-12-31 | 0.59% | ₩350.05 Million ≈ $237.22K |
₩59.20 Billion ≈ $40.12 Million |
+0.58pp |
| 2014-12-31 | 0.01% | ₩4.68 Million ≈ $3.17K |
₩62.17 Billion ≈ $42.13 Million |
-- |
About Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more